Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Phio Pharmaceuticals is a clinical-stage biotech company developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference technology. Its focus is on creating targeted cancer treatments that enhance immune cell effectiveness without complex delivery systems. The company’s pipeline includes gene-silencing compounds like PH-762, targeting proteins such as PD-1, aimed at treating various cancers through intratumoral injections and adoptive cell therapy.
This description was generated via AI from an annual report. Updated about 1 year ago.